1. Future Directions for Zoledronic Acid and New Agents for the Treatment of Bone Metastases 
Yong-jiang Hei 
European Urology Supplements 
Volume 3, Issue 5, Pages (November 2004)
DOI: /j.eursup
Copyright © 2004 Elsevier B.V. Terms and Conditions

2. Fig. 1
Zoledronic acid provides clinical benefit throughout the continuum of care for patients with prostate cancer. CTIBL: cancer treatment-induced bone loss; BMD: bone mineral density; BM: bone metastasis; SRE: skeletal-related event; TBD: to be determined.
European Urology Supplements 2004 3, 55-62DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

3. Fig. 2
Platelet-derived growth factor receptor inhibitor, imatinib, reduces bone loss and tumor incidence in vivo. Digital radiography of PC3-MM2–derived bone tumors growing in hind legs of nude mice shows that 5-week treatment with imatinib, with or without paclitaxel, resulted in significant reductions in tumor incidence, tumor size, and bone destruction compared with control or paclitaxel alone (p < 0.001). Adapted with permission from Uehara et al. [33].
European Urology Supplements 2004 3, 55-62DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

4. Fig. 3
Inhibition of cathepsin K with SB significantly reduces bone resorption in vivo. Estrogen-deficient monkeys were treated with the cathepsin K inhibitor SB or vehicle once daily for 5 days. Serum levels of N-telopeptide (NTx) were measured on day 1 before dosing and at 1.5, 4, and 24hours after dosing, and on day 5 before dosing and 1.5 and 4hours after dosing. Data are expressed as mean percentage of baseline. *p < 0.05; †p < Adapted from Stroup et al. [46] with permission of the American Society for Bone and Mineral Research.
European Urology Supplements 2004 3, 55-62DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions